BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Clinical trials for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) explained in plain language.
Never miss a new study
Get alerted when new BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) trials appear
Sign up with your email to follow new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a personalized cell therapy called CART123 for adults with certain blood cancers (like acute myeloid leukemia) that have not responded to standard treatments. Each patient's own immune cells are collected, modified to target the CD123 protein on cance…
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
Rare cancer registry aims to unlock treatment secrets
Knowledge-focused Recruiting nowThis study is creating a worldwide database of people with a very rare blood cancer called BPDCN. Researchers will collect information on how the disease appears, how it is treated, and what happens to patients over time. The goal is to learn from real-world cases to help doctors…
Matched conditions: BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN)
Sponsor: Immune Oncology Research Institute • Aim: Knowledge-focused
Last updated Jun 17, 2026 02:42 UTC